Lakewood-amedex Biotherapeutics INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Lakewood-Amedex Biotherapeutics Inc. has released an investor presentation detailing its Bisphosphocin compounds, focusing on the lead program Nu-3 for infected diabetic foot ulcers.
NASDAQ
Lakewood-Amedex Biotherapeutics Inc. has filed a Form 8-K announcing a 1-for-10 reverse stock split to become effective on June 19, 2026, with trading on a split-adjusted basis commencing June 22, 2026.
NASDAQ
Lakewood-Amedex Biotherapeutics Inc. announced the appointment of Dr. Joseph Tucker to its Board of Directors, effective April 24, 2026, to enhance governance and strategic capabilities.